TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10910310
Drug: Omeprazole sodium,
Normalized name: Esomeprazole Sodium, 20 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole sodium, 20 mg once daily
Study: 9263160
Drug: morphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine (0.3 mg/kg)
Study: 9263160
Drug: lidocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidocaine (5 mg/kg)
Study: 9263160
Drug: ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine (0.3 mg/kg)
Study: 3307623
Drug: Oral ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral ribavirin treatment
Study: 31296264
Drug: Innovative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative and stepped structural case management program for depression treatment in nursing home residents.
Study: 27836532
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care plus 20 jumps twice daily
Study: 21319341
Drug: Diacerein treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diacerein treatment group (n = 12)
Study: 20015431
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Yunchang Capsule (0.35 g/pill, 2 pills + 1 simulant pill, three times daily)
Study: 20015431
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Yunchang Capsule (0.35 g/pill, 3 pills, three times daily)
Study: 20015431
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Biantong Capsule, 0.35 g/pill, 3 pills, three times daily)
Study: 20015431
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Yunchang Capsule
Study: 20015431
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Yunchang Capsule
Study: 20015431
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Biantong Capsule)
Study: 16428355
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml sterile water as placebo (group 1, n = 10)
Study: 16428355
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 33% sucrose solution (group 2, n = 10)
Study: 16428355
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml sterile water with pacifier (group 3, n = 9)
Study: 16428355
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml 33% sucrose solution with pacifier (group 4, n = 11)
Study: 12847731
Drug: Pollen immunotherapy
Normalized name: Pollen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pollen immunotherapy
Study: 12847731
Drug: Low‐molecular‐weight allergen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐molecular‐weight allergen peptide vaccines
Study: 17563272
Drug: Clopidogrel loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel loading dose of 300 mg 6-24 hours before intervention and maintenance for 1 month
Study: 17563272
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment continued for at least 24 months
Study: 17563272
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment after 6 months from bare-metal stenting
Study: 9707350
Drug: Fludrocortisone (Florinef)
Normalized name: fludrocortisone acetate Oral Tablet [Florinef]
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone (Florinef) therapy for orthostatic hypotension
Study: 9707350
Drug: No fludrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No fludrocortisone therapy
Study: 9200279
Drug: 150‐mg ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150‐mg ranitidine effervescent tablets
Study: 9200279
Drug: 20‐mg famotidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20‐mg famotidine wafers
Study: 2293218
Drug: ACC-9653 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-9653 administered alone
Study: 2293218
Drug: ACC-9653 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-9653 administered concomitantly with diazepam
Study: 2293218
Drug: ACC-9653 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC-9653 and diazepam administered together
Study: 7271345
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 g in operating room plus 3,578 mg average during the next three days)
Study: 27550954
Drug: Crushed immediate-release
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed immediate-release oxycodone 40 mg
Study: 27550954
Drug: Crushed ALO-02
Normalized name: miconazole nitrate 0.02 MG/MG [Aloe Vesta Antifungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed ALO-02 40 mg/4.8 mg
Study: 27550954
Drug: Crushed ALO-02
Normalized name: miconazole nitrate 0.02 MG/MG [Aloe Vesta Antifungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed ALO-02 60 mg/7.2 mg
Study: 27550954
Drug: Intact ALO-02
Normalized name: miconazole nitrate 0.02 MG/MG [Aloe Vesta Antifungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact ALO-02 60 mg/7.2 mg
Study: 26093827
Drug: Deferasirox (DEFR)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox (DEFR) administered BID (40 mg/kg)
Study: 26093827
Drug: Deferasirox (DEFR)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox (DEFR) administered once daily (30 or 40 mg/kg)
Study: 22686074
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (IM) treatment for diabetic nephropathy
Study: 20151768
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera) titrated once weekly
Study: 20151768
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera) titrated twice weekly
Study: 16222890
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin once daily orally (n = 40)
Study: 16222890
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alfuzosin once daily orally (n = 36)
Study: 10102945
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Study: 10102945
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Study: 10102945
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.d., clarithromycin 500 mg b.d., amoxycillin 1 g b.d.
Study: 10102945
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d., tetracycline 500 mg t.d.s., tinidazole 500 mg b.d.
Study: 7757313
Drug: Antipyrine powder
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine powder (1,050 mg)
Study: 7757313
Drug: Antipyrine capsule
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine capsule (1,050 mg)
Study: 7757313
Drug: Antipyrine powder
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine powder and capsule formulations
Study: 7757313
Drug: Antipyrine capsule
Normalized name: Antipyrine
DrugBank: Antipyrine (DB01435)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyrine capsule formulation
Study: 37697
Drug: Clopimozide (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopimozide (average optimum daily dose of 13.95 mg)
Study: 30074112
Drug: Ticagrelor combined
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor combined with aspirin
Study: 11124134
Drug: Triglyceride (Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride (Intralipid 20%, 1.5 ml/min) and heparin (bolus: 200 IU; constant infusion rate: 0.2 IU.kg(‐1).min(‐1))
Study: 10381989
Drug: Ipratropium with
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium with beta-agonists
Study: 24338756
Drug: Conventional Colonoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Colonoscopy (CC)
Study: 24074299
Drug: Online psychological
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online psychological treatment
Study: 2574555
Drug: Hydroxyzine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine, 25 mg qid
Study: 21269305
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral antibiotics for 4 weeks)
Study: 18185995
Drug: KEEP (Keeping
Approvals — FDA: no, EMA: no, PMDA: no
Description: KEEP (Keeping Foster Parents Trained and Supported) based on Multidimensional Treatment Foster Care (MTFC)
Study: 16877984
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) combined with IV propofol (0.5 mg/kg)
Study: 16877984
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam combined with IV propofol
Study: 10966534
Drug: D-Dimer level
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Dimer level >500 microg/L
Study: 8941062
Drug: 2.5 mg/d
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/d MPA plus 0.625 mg/d conjugated estrogens (group A: 31 patients)
Study: 8941062
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d estrone sulfate (group B: 28 patients)
Study: 1609752
Drug: 1.4 mg
Normalized name: phenol 1.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg Zn/d
Study: 1609752
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg Zn/d
Study: 1609752
Drug: 3.4 mg
Normalized name: urea 83.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 mg Zn/d
Study: 1609752
Drug: 10.4 mg
Normalized name: cisapride 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.4 mg Zn/d
Study: 31468596
Drug: Lycopene 25
Normalized name: lycopene 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene 25 mg
Study: 29167971
Drug: Abaloparatide-SC 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-SC 20 μg
Study: 29167971
Drug: Abaloparatide-SC 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-SC 40 μg
Study: 29167971
Drug: Abaloparatide-SC 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abaloparatide-SC 80 μg
Study: 29167971
Drug: Subcutaneous teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous teriparatide 20 μg
Study: 23756850
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (prednisolone + lamivudine)
Study: 23756850
Drug: Monotherapy (prednisolone)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (prednisolone)
Study: 22040285
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) intervention consisting of three 2-hr group sessions scheduled during a single week.
Study: 20227241
Drug: web‐based therapist‐assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: web‐based therapist‐assisted cognitive behavioral treatment (web‐CBT)
Study: 17765381
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of dimenhydrinate
Study: 12512792
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment protocol as defined by consensus among acupuncture trainers
Study: 10329342
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes of brisk walking in any combination of bouts (minimum 5 minutes each)
Study: 1742749
Drug: L-threonine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine 4.5 g/day
Study: 1742749
Drug: L-threonine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-threonine 6.0 g/day
Study: 6891929
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg b.d. (P)
Study: 6891929
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg b.d. (T)
Study: 27669638
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule
Study: 27065056
Drug: P2Y12-receptor specific
Normalized name: PACIFIC OYSTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2Y12-receptor specific assay (ADPtest HS)
Study: 24685414
Drug: Standard Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Regimen + individualized homeopathic medicine (SR + H)
Study: 19039231
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy to maintain strict normoglycemia (below 110 mg/dl)
Study: 19039231
Drug: Strict blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict blood glucose control with intensive insulin therapy
Study: 18088216
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) delivered in school or clinic settings by trained clinicians
Study: 15333734
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) with high isoflavone content (mean intake 96 mg/d)
Study: 15333734
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein isolate (SPI) with low isoflavone content (mean intake 6 mg/d)
Study: 11441210
Drug: Constraint-induced (CI)
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced (CI) aphasia therapy
Study: 2541985
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (6.6 g/bar, average consumption 31.7 g/day)
Study: 21118735
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 20 mg BID (group A)
Study: 21118735
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Esomeprazole 40 mg BID (group B)
Study: 21118735
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg/d and Amoxicillin 1000 mg BID plus Rabeprazole 10 mg BID (group C)
Study: 16368293
Drug: Methotrexate (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5 mg once a week, n = 35)
Study: 15753186
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil plus different doses of vitamin E for 3 months
Study: 8454221
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine
Study: 3773599
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dipyrone, pitofenone and fenpipramide (control)
Study: 29516425
Drug: Topical fusidic
Normalized name: fusidate Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fusidic acid (2%) and recombinant human interferon after ALA-PDT
Study: 19016941
Drug: BIMS (Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIMS (Brief Interview of Mental Status) administered by research assistants
Study: 19016941
Drug: BIMS (Brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIMS (Brief Interview of Mental Status) administered by facility nurses
Study: 12778045
Drug: Ethical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethical treatment and motivation of participants
Study: 8780817
Drug: Alternating therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating therapy (ZDV/ddI)
Study: 8780817
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) therapy (monotherapy or alternating)
Study: 1600993
Drug: gallopamil 150
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gallopamil 150 mg daily for 4 weeks
Study: 1600993
Drug: nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 60 mg daily for 4 weeks
Study: 6541198
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: rifampin 600 mg twice weekly, prothionamide 500 mg, and dapsone (DDS) 100 mg daily for six months, followed by 100 mg DDS daily for another six months
Study: 24793093
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine (IV BUP)
Study: 24793093
Drug: Intranasal buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buprenorphine (IN BUP)
Study: 19680659
Drug: 900 ml
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 ml of low-density barium sulphate (LDB) (group C)
Study: 19680659
Drug: 900 ml
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 ml of low-density barium sulphate (LDB) (groups C, D, E)
Study: 19680659
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral contrast agent (group A)
Study: 19680659
Drug: 900 ml
Normalized name: OXYGEN 900 mL in 1 L RESPIRATORY (INHALATION) GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 ml of water (group B)
Study: 18559644
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oral oseltamivir every 24 h (group 1)
Study: 18559644
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oseltamivir every 48 h combined with 500 mg probenecid four times a day (group 2)
Study: 18559644
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg oseltamivir q48h combined with 500 mg probenecid twice a day (group 3)
Study: 12215687
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.2 mg/ml
Study: 12215687
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.4 mg/ml
Study: 12215687
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.2 mg/ml and 0.4 mg/ml
Study: 10667741
Drug: Haloperidol or
Normalized name: haloperidol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol or another conventional antipsychotic
Study: 7541769
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH (0.125 IU/kg/week)
Study: 7541769
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH (0.5 IU/kg/week)
Study: 2116083
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 mg/day for 6 months)
Study: 2116083
Drug: Control (non-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-medication group)
Study: 877639
Drug: Spray containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray containing a local anesthetic plus an antiseptic agent
Study: 28333029
Drug: Diluted hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diluted hyaluronidase (8 IU/mL)
Study: 28333029
Drug: Normal hyaluronidase
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Normal hyaluronidase (80 IU/mL)
Study: 25843912
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of 5-aminolevulinic acid (5-ALA)
Study: 25843912
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg of 5-aminolevulinic acid (5-ALA)
Study: 23816561
Drug: Sinusoidal chronomodulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinusoidal chronomodulated infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Study: 23816561
Drug: Flat intermittent
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flat intermittent constant rate infusion of cisplatin (DDP) and 5‐fluorouracil (5‐FU)
Study: 21356150
Drug: Six servings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six servings of low glycaemic index (LGI) foods daily
Study: 21356150
Drug: Eight servings
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight servings of low glycaemic index (LGI) foods daily
Study: 17405995
Drug: Chemotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (standard chemotherapy, 87% received cyclophosphamide, methotrexate, and 5-fluorouracil; 11% received anthracycline-containing regimens)
Study: 17405995
Drug: Chemotherapy (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (standard chemotherapy)
Study: 8787073
Drug: Drug (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug (specific drug not mentioned)
Study: 6131857
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 150 mg ranitidine